Prevail Therapeutics’ PR006 Fast Track’d to slow progression of some dementias

The FDA has granted Fast Track Designation for Prevail Therapeutics’ (NASDAQ:PRVL) experimental gene therapy program, PR006, to slow the progression of frontotemporal dementia with a GRN mutation (FTD-GRN).

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

https://seekingalpha.com/news/3554591-prevail-therapeutics-pr006-fast-trackd-to-slow-progression-of-ftd-grn